AbbVie

708 articles with AbbVie

• 

  AbbVie, Calibr Collaborate to Develop Next-Generation CAR-T Therapies for Sol...

  6/25/2018

  AbbVie is taking another shot at solid tumor treatments through a collaboration with Calibr.

• AbbVie and Calibr announce collaboration for next generation T-cell therapies

  6/25/2018

  Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors

• 

  ObsEva Therapeutic Shows Reduction of Pain in Mid-Stage Endometriosis Trial

  6/18/2018

  Ernest Loumaye, chief executive officer of Switzerland-based ObsEva, is excited about the potential opportunity to provide women a significant treatment for endometriosis-associated pain.

• AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress

  6/15/2018

  83 percent of 121 patients who achieved undetectable minimal residual disease at the end of combination therapy with VenR, maintained uMRD and were progression-free at 13.8 months of follow-up

• 

  Spotlight on Biopharma Fellowships: AbbVie and Keck Graduate Institute Launch PharmD Fellowship P...

  6/14/2018

  AbbVie and the Keck Graduate Institute (KGI) School of Pharmacy have partnered to form the first AbbVie-KGI Biopharmaceutical Industry Fellowship.

• AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)

  6/12/2018

  AbbVie presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam

• E-Scape Bio Obtains Worldwide Rights from AbbVie for Selective S1P5 Program Targeting CNS-related Lysosomal Storage Disorders

  6/12/2018

  E-Scape adds late pre-clinical program to pipeline of genetically defined programs to treat CNS disorders. AbbVie will become an investor in E-Scape.

• 

  AbbVie Responds to FDA Criticism Over Manufacturing Complaints

  6/12/2018

  The U.S. Food and Drug Administration (FDA) recently reprimanded AbbVie for its processes for investigating reports of deaths associated with three of its drugs.
• 

  AbbVie and Roche’s Venclexta and Rituxan Combo Gets FDA Approval

  6/11/2018

  The U.S. Food and Drug Administration (FDA) approved AbbVie and Roche’s combination of Venclexta in combination with Rituxan (rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion in patients who have received at least one previou...

• AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

  6/8/2018

  AbbVie announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA® (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL)

• Genentech Announces FDA Approval for Venclexta Plus Rituxan for People with Previously Treated Chronic Lymphocytic Leukemia

  6/8/2018

  Genentech announced today that the U.S. Food and Drug Administration (FDA) has approved Venclexta® in combination with Rituxan® for the treatment of people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

• The Institute for Research in Immunology and Cancer receives funding support from AbbVie for its work involving acute myeloid leukemia, paving the way to developing a cancer vaccine

  6/5/2018

  The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal is proud to announce that it has received funding support from AbbVie

• Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

  6/5/2018

  - In SELECT-EARLY, upadacitinib monotherapy (15/30 mg, once-daily) met both primary endpoints, with 52/56 percent of methotrexate-naïve patients achieving ACR50 at week 12 and 48/50 percent achieving clinical remission at week 24, respectively(1)

• 

  AbbVie’s Upadacitinib Looks Good in Arthritis Trial; Rova-T Looks Worse in Lung Cancer

  6/5/2018

  AbbVie announced positive topline results from its SELECT-EARLY Phase III clinical trial in rheumatoid arthritis, but disappointed with Rova-T small-cell lung cancer therapy.

• AbbVie Teams Up with Hidradenitis Suppurativa Patients Around the World to Raise Awareness About the Disease

  6/4/2018

  AbbVie announced the launch of Voices of HS Unite, a global social media effort to connect and inspire those impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin disease.

• AbbVie Announces Final Results of Modified Dutch Auction Tender Offer

  6/4/2018

  AbbVie announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018.

• 

  BIO 2018 is the International Convention’s 25th Year

  6/4/2018

  The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.

• Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

  6/3/2018

  AbbVie announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA® (venetoclax) in previously-untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.

• Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone

  6/1/2018

  AbbVie announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA® (ibrutinib) plus RITUXAN® (rituximab).

• Halozyme Identifies Plasma Biomarkers As Potential Predictors Of Survival In Pancreatic Cancer

  6/1/2018

  Halozyme Therapeutics, Inc. will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology annual meeting.